Suppr超能文献

趋化因子(C-C 基序)配体 21 和 SPARC 样蛋白 1 的生物信息学分析揭示了它们与卵巢癌耐药性的关联。

Bioinformatic analysis of chemokine (C-C motif) ligand 21 and SPARC-like protein 1 revealing their associations with drug resistance in ovarian cancer.

机构信息

Department of Gynecologic Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.

出版信息

Int J Oncol. 2013 Apr;42(4):1305-16. doi: 10.3892/ijo.2013.1819. Epub 2013 Feb 8.

Abstract

Chemokine (C-C motif) ligand 21 (CCL21) and SPARC-like protein 1 (SPARCL1/MAST9/hevin/SC-1) are associated with various biological behavior in the development of cancers. Although the expression of CCL21 and SPARCL1 is downregulated in many solid tumors, their roles in ovarian cancer and their associations with drug resistance have rarely been studied. We performed a comprehensive bioinformatic analysis consisting of motif analysis, literature co-occurrence, gene/protein-gene/protein interaction network, protein-small molecule interaction network, and microRNAs enrichments which revealed that CCL21 and SPARCL1 directly or indirectly interact with a number of genes, proteins, small molecules and pathways associated with drug resistance in ovarian and other cancers. These results suggested that CCL21 and SPARCL1 may contribute to drug resistance in ovarian cancer. This study provided important information for further investigation of drug resistance-related functions of CCL21 and SPARCL1 in ovarian cancer.

摘要

趋化因子(C-C 基序)配体 21(CCL21)和 SPARC 样蛋白 1(SPARCL1/MAST9/hevin/SC-1)与癌症发展中的各种生物学行为有关。虽然 CCL21 和 SPARCL1 在许多实体瘤中表达下调,但它们在卵巢癌中的作用及其与耐药性的关系很少被研究。我们进行了一项综合的生物信息学分析,包括基序分析、文献共现、基因/蛋白质-基因/蛋白质相互作用网络、蛋白质-小分子相互作用网络和 microRNAs 富集,结果表明 CCL21 和 SPARCL1 直接或间接与许多与卵巢癌和其他癌症耐药性相关的基因、蛋白质、小分子和途径相互作用。这些结果表明 CCL21 和 SPARCL1 可能有助于卵巢癌的耐药性。本研究为进一步研究 CCL21 和 SPARCL1 在卵巢癌中与耐药性相关的功能提供了重要信息。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验